Close

Form 6-K BioLineRx Ltd. For: Dec 21

December 21, 2015 11:31 AM EST


SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of December 2015
_______________________
 
BioLineRx Ltd.
 (Translation of registrant’s name into English)
_______________________
 
2 HaMa’ayan Street
Modi’in 7177871, Israel
 (Address of Principal Executive Offices)
_______________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:         
 
Form 20-F þ   Form 40-F o
 
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:           
 
Yes o   No þ
 
 
 

 
 
The Registrant hereby announces the departure of Leah Klapper, Ph.D, its Chief Scientific Officer, effective December 31, 2015. The Registrant is currently meeting with potential candidates in order to fill the position. Dr. Klapper will continue to provide services to the Registrant as a consultant.
 
This report on Form 6-K is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
 
 
 

 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
BioLineRx Ltd.
 
 
  By:
/s/ Philip Serlin
 
   
Philip Serlin
 
   
Chief Financial and Operating Officer
 
 
Dated: December 21, 2015
 
 




Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings